Can Novel Myosin Inhibitors Defer Septal Reduction Therapy in HCM? At What Risk and at What Cost?

Circulation. 2023 Mar 14;147(11):864-866. doi: 10.1161/CIRCULATIONAHA.122.063383. Epub 2023 Mar 13.

Authors

Harry Rakowski¹, Roxana Bataiosu^{1

2}

Affiliations

¹ Division of Cardiology, Peter Munk Cardiac Centre, Department of Medicine, Toronto General Hospital, Ontario, Canada (H.R., R.B.).
² Department of Cardiology, University Heart Center, University Hospital Zurich, Switzerland (E.B.).

PMID: 36913498
DOI: 10.1161/CIRCULATIONAHA.122.063383

No abstract available

Keywords: Editorials; cardiomyopathy, hypertrophic obstructive; therapy.

Publication types

Editorial
Comment

MeSH terms

Cardiomyopathy, Hypertrophic*
Humans
Myocardium*
Myosins

Substances

Myosins